AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21322021
Drug: Rotigotine (2-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (2-16 mg/24 hr)
Trial: 19818700
Drug: Acute painful
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute painful edematous stage treatment (surgery or conservative)
Trial: 17268412
Drug: Pre-dosing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-dosing with 5 x 100 mg LU
Trial: 17268412
Drug: Without pre-dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without pre-dosing
Trial: 17268412
Drug: One week
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week after pre-dosing
Trial: 17268412
Drug: Three weeks
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weeks after pre-dosing
Trial: 7560253
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHCl
Trial: 7560253
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg PHCl
Trial: 7560253
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHCl and 80 mg PHCl
Trial: 2090337
Drug: 2.5% topical
RxNorm normalized name: BP 2.5% Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% topical ocular phenylephrine hydrochloride
Trial: 2090337
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical ocular phenylephrine hydrochloride
Trial: 22449646
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch plus CBT
Trial: 15871756
Drug: Intermittent Positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Positive Expiratory Pressure (PEP) therapy, n = 11
Trial: 12477218
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (24 microg bid)
Trial: 12477218
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 microg b.i.d.)
Trial: 26577258
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (10 patients)
Trial: 20925517
Drug: MAF (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAF (0.5% ophthalmic solution with retention-enhancing agent)
Trial: 20925517
Drug: Moxi (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxi (0.5% ophthalmic solution)
Trial: 19544682
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac plus B vitamins (thiamine, pyridoxine, cyanocobalamin)
Trial: 2181621
Drug: Enteric-coated naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated naproxen tablets
Trial: 2181621
Drug: Plain naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain naproxen tablets
Trial: 28701677
Drug: Tolvaptan in
RxNorm normalized name: Product containing tolvaptan in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan in addition to conventional diuresis therapy
Trial: 28701677
Drug: Conventional diuresis
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuresis therapy only (control group)
Trial: 18191455
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (assertive community treatment, psycho-educational multi-family groups, social skills training)
Trial: 12828753
Drug: Lithium gluconate
RxNorm normalized name: lithium gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium gluconate 8% ointment
Trial: 10900994
Drug: Self-selected treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected treatment clients
Trial: 27330150
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 2 g tranexamic acid (TA) diluted in 200 ml of saline
Trial: 27330150
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of saline (placebo group)
Trial: 27330150
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical administration (control group)
Trial: 19854632
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS reminder
Trial: 20529769
Drug: Candid #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candid #1 vaccine (Argentina)
Trial: 20529769
Drug: USA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USA vaccine
Trial: 17036474
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (oral administration)
Trial: 15707013
Drug: Telmisartan (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20‐80 mg)
Trial: 15707013
Drug: Enalapril (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5‐10 mg)
Trial: 11526531
Drug: Octreotide-LAR (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide-LAR (20 mg)
Trial: 9031963
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose estradiol released from a vaginal ring (Estring)
Trial: 9031963
Drug: Estriol vaginal
RxNorm normalized name: estriol Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol vaginal cream (Synapause)
Trial: 8428468
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg) by iv infusion every 6 hrs for four doses
Trial: 3593895
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily) in elderly subjects
Trial: 27390049
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of pidotimod
Trial: 12920692
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors (general)
Trial: 10571597
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg twice daily (n=319)
Trial: 10571597
Drug: Mebeverine 135
RxNorm normalized name: mebeverine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 135 mg three times daily (n=304)
Trial: 8916244
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (outpatient setting)
Trial: 1841578
Drug: Mitomycin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin (0.2 mg) applied once during trabeculectomy
Trial: 1841578
Drug: Fluorouracil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (5 mg) injected subconjunctivally 10 times in 2 weeks after surgery
Trial: 6357204
Drug: Orgotein (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein (2 mg)
Trial: 18824917
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (30 ppm) + glucocorticoids (2 mg/kg)
Trial: 18824917
Drug: Placebo (nitrogen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (nitrogen) + glucocorticoids (2 mg/kg)
Trial: 11803256
Drug: drug‐free W/O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug‐free W/O vehicle
Trial: 10332446
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral paroxetine as needed 3 to 4 hours before planned intercourse (Study 1)
Trial: 10332446
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg paroxetine daily for 3 weeks and then 20 mg paroxetine as needed for 4 weeks (Study 2)
Trial: 10332446
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 3 weeks and then placebo as needed for 4 weeks (Study 2)
Trial: 10332446
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily and placebo as needed (Study 2)
Trial: 8750371
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of ardeparin
Trial: 29742189
Drug: Nutrafol® Women's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrafol® Women's Capsules (active treatment)
Trial: 25027424
Drug: Norvancomycin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norvancomycin and heparin saline mixture
Trial: 25027424
Drug: Heparin saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin saline
Trial: 22318947
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg/day with a 36-h interval)
Trial: 20558919
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of LAM plus ADV combination therapy
Trial: 20558919
Drug: Overlap/switch to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overlap/switch to adefovir dipivoxil (ADV) monotherapy
Trial: 20558919
Drug: Overlap/switch to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overlap/switch to ADV monotherapy
Trial: 21418991
Drug: rhIL‐11 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL‐11 injection
Trial: 12110838
Drug: Venom immunotherapy
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venom immunotherapy (VIT)
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 at doses of 0.05 to 0.9 mg
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 at doses up to 0.6 mg
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 at 0.9 mg
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 at doses of 1.5 mg to 3.9 mg
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 (all dose groups)
Trial: 9542482
Drug: DMP 728
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMP 728 (all doses)
Trial: 15374302
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Aramexe retard
Trial: 15374302
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Hydergine
Trial: 3391873
Drug: Erythromycin acistrate
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin acistrate (EA) 400 mg tid for 10 days
Trial: 3391873
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate (ES) 500 mg tid for 10 days
Trial: 31755220
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination (entecavir plus Peg‐interferon [IFN]α‐2a co‐administration during year 1)
Trial: 31755220
Drug: Late combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late combination (addition of Peg‐IFNα‐2a for 48 weeks after 1 year of entecavir)
Trial: 31755220
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogue (NA) monotherapy
Trial: 31755220
Drug: Non-antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antiviral treatment
Trial: 29633918
Drug: Novel device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel device for preoperative skin preparation
Trial: 29633918
Drug: Current techniques
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current techniques of skin preparation
Trial: 27506926
Drug: High-sensitivity troponin
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity troponin T (hs‐TnT) reporting among patients with troponin levels <30 ng/L
Trial: 27506926
Drug: Standard reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard reporting (std‐report) among patients with troponin levels <30 ng/L
Trial: 23657308
Drug: Alanyl-glutamine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl-glutamine (24 g/day)
Trial: 23657308
Drug: Placebo (glycine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycine, 25 g/day)
Trial: 20734845
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Mallampati test, Patila test, and ULBT test
Trial: 19006471
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g P‐OM3 plus 40 mg rosuvastatin
Trial: 16015260
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E co-supplementation with multi-drug therapy (MDT)
Trial: 16015260
Drug: Multi-drug therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug therapy (MDT)
Trial: 12970290
Drug: Oral 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17beta‐estradiol 2 mg combined with trimegestone 0.5 mg (E(2)+T)
Trial: 12970290
Drug: Oral 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17beta‐estradiol 2 mg combined with dydrogesterone 10 mg (E(2)+D)
Trial: 1387369
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 mg twice daily for 12 months)
Trial: 30776296
Drug: rhG‐CSF (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG‐CSF (130 μg daily subcutaneous injections for a maximum of 9 weeks)
Trial: 30776296
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical appearing injections for a maximum of 9 weeks)
Trial: 16050428
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen patches (100 microg per day)
Trial: 2484789
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment of 8 Gy
Trial: 793780
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ketoprofen per day
Trial: 793780
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg indomethacin per day
Trial: 31717901
Drug: Fibre supplementation
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplementation (twice-a-day)
Trial: 21277837
Drug: Aceclofenac-CR (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac-CR (n = 143) once daily
Trial: 21277837
Drug: Conventional aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional aceclofenac (n = 142) twice daily
Trial: 11778097
Drug: Continuous cervical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cervical plexus block with ropivacaine 0.75% 2.5 mg/kg
Trial: 11778097
Drug: Continuous cervical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cervical peridural anaesthesia with ropivacaine 0.5% 0.9 mg/kg and fentanyl 50-100 g
Trial: 9424681
Drug: vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.01 mg/kg
Trial: 7690527
Drug: Terfenadine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 120 mg bid
Trial: 7690527
Drug: Terfenadine, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 240 mg bid
Trial: 7690527
Drug: Ketotifen, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen, 2 mg bid
Trial: 24832787
Drug: Circulating tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating tumor cells (CTCs) detected before chemotherapy
Trial: 24832787
Drug: Circulating tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating tumor cells (CTCs) detected after chemotherapy
Trial: 24832787
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of at least five CTCs per 30 mL blood
Trial: 24832787
Drug: Persisting CTCs
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persisting CTCs after chemotherapy
Trial: 12692962
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with radiation therapy of the involved field (specific chemotherapy regimen not detailed, but mentions CHOP cycles).
Trial: 12692962
Drug: Short-course chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course chemotherapy (3 cycles of CHOP) for low bulk tumors.
Trial: 12692962
Drug: Full-course chemotherapy
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-course chemotherapy (6-8 cycles of CHOP) for larger tumors.
Trial: 10779656
Drug: Oral dextromethorphan
RxNorm normalized name: dextromethorphan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextromethorphan 150 mg
Trial: 3134905
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate treatment
Trial: 26887521
Drug: Improved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved treatment group (400 µg folic acid daily from the day before the first dose to 21 days after the last dose, 500 µg vitamin B12 injection one day before the first dose and before each therapy cycle)
Trial: 26887521
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (400 µg folic acid daily for 7 days before the first dose and continued until 21 days after the last dose, 1000 µg vitamin B12 injection at 7 days before the first dose and once per cycle for 3 cycles after the last dose)
Trial: 26887521
Drug: Improved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved treatment group
Trial: 18312649
Drug: Self‐Administered Mailed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐Administered Mailed Questionnaire (SAMQ)
Trial: 16970600
Drug: Weight-based RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based RBV dosing
Trial: 8881626
Drug: Ketamine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 3 mg kg-1 nasally (group IN3)
Trial: 8881626
Drug: Ketamine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 9 mg kg-1 nasally (group IN9)
Trial: 8881626
Drug: Ketamine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 9 mg kg-1 rectally (group IR9)
Trial: 8881626
Drug: Ketamine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 3 mg kg-1 i.v. (group IV3)
Trial: 8881626
Drug: Rectal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal ketamine (group IR9)
Trial: 8881626
Drug: Norketamine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norketamine after nasal administration
Trial: 3890924
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg daily, doubled after 3 months if inadequate response)
Trial: 3890924
Drug: Griseofulvin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (500 mg daily, doubled after 3 months if inadequate response)
Trial: 29338639
Drug: Continuous Passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Passive Motion (CPM) combined with Complete Decongestive Therapy (CDT)
Trial: 29338639
Drug: Complete Decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Decongestive Therapy (CDT) alone
Trial: 24215171
Drug: ABT-288 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 (10 dose levels, from 1 to 60 mg once daily for 14 days)
Trial: 20929341
Drug: Margarine supplemented
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margarine supplemented with EPA and DHA (targeted additional daily intake of 400 mg of EPA-DHA)
Trial: 20929341
Drug: Margarine supplemented
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margarine supplemented with ALA (targeted additional daily intake of 2 g of ALA)
Trial: 15763436
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion therapy